Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Hold
0
-$189K 567
2025
Q1
Hold
0
495
2024
Q3
Hold
0
-$257K 513
2024
Q2
Hold
0
416
2023
Q1
Hold
0
-$48.5K 384
2022
Q4
Hold
0
400
2020
Q4
Sell
-1,000
Closed -$88K 325
2020
Q3
$88K Buy
+1,000
New +$94.1K 0.01% 277
2020
Q1
Sell
-200,000
Closed -$177K 252
2019
Q4
$177K Buy
+200,000
New +$16.6M 0.02% 241

Other funds holding ABBV

SteelPeak Wealth's ABBV Position: Q2 2026 in Review

SteelPeak Wealth increased its AbbVie (ABBV) stake by 1% in Q2 2026, buying an estimated $80K and bringing the position to 37,009 shares worth $9.31M. The position accounts for 0.24% of the portfolio, ranked #86.

SteelPeak Wealth first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $9.36M in Q4 2025. 2,049 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • SteelPeak Wealth held 37,009 shares of AbbVie worth $9.31M as of Q2 2026.
  • SteelPeak Wealth bought 372 AbbVie shares in Q2 2026, an estimated $80K.
  • AbbVie made up 0.24% of SteelPeak Wealth's portfolio in Q2 2026, its #86 holding.
  • SteelPeak Wealth first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • SteelPeak Wealth's AbbVie position peaked at $9.36M in Q4 2025.
  • 2,049 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on SteelPeak Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.